Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

Cited by (237)

Items 101–200 of 237

1. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model
   Saffire Hanna Krance, Hugo Cogo‐Moreira, Jennifer S. Rabin, Sandra E. Black, Walter Swardfager · 2019 · Journal of Neuroscience
2. The ADNI PET core at 20
   Jagust, William J., Koeppe, Robert A., Rabinovici, Gil D., Villemagne, Victor L., Harrison, Theresa M., Landau, Susan M., the Alzheimer's Disease Neuroimaging Initiative · 2024 · Alzheimer's & Dementia
3. Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment
   Philip S. Insel, Michael Donohue, R. Scott Mackin, Paul S. S Aisen, Oskar Hansson, Michael Walter Weiner, Niklas Mattsson · 2016 · Neurobiology of Aging
4. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
   Ronald Lautner, Philip S. Insel, Tobias Borgh Skillbäck, Bob Olsson, Mikael Landén, Giovanni Battista Frisoni, Sanna‐Kaisa Herukka, Harald Juergen Hampel, Anders Wallin, Lennart Minthon et al. · 2017 · Alzheimer s Research & Therapy
5. Reduced brain amyloid burden in elderly patients with narcolepsy type 1
   Audrey Gabelle, Isabelle Jaussent, Fayçal Ben Bouallègue, Sylvain Lehmann, Régis Lopez, Lucie Barateau, Caroline Grasselli, Carole Pesenti, Delphine de Verbizier, Séverine Béziat et al. · 2018 · Annals of Neurology
6. Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on18F-Florbetapir PET Using ADNI Data
   Fabian H. Reith, Mary Ellen I. Koran, Guido Davidzon, Greg Zaharchuk · 2020 · American Journal of Neuroradiology
7. Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease
   Sebastian G. Popescu, Alex Whittington, Roger N. Gunn, Paul McMahan Matthews, Ben Glocker, David James Sharp, James Howard Cole, Alzheimer’s Disease Neuroimaging Initiative · 2020 · Human Brain Mapping
8. Amyloid Network Topology Characterizes the Progression of Alzheimer’s Disease During the Predementia Stages
   Joana B. Pereira, Tor Olof Strandberg, Sebastian Palmqvist, Giovanni Volpe, Danielle van Westen, Eric Westman, Oskar Hansson, Alzheimer’s Disease Neuroimaging Initiative · 2017 · Cerebral Cortex
9. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer’s Disease?
   Maria Travassos, Isabel J. Santana, Inês Baldeiras, Magda Tsolaki, Olymbia Gkatzima, Şermin Genç, Görsev Yener, Anja Hviid Simonsen, Steen Gregers Hasselbalch, Elisabeth N. Kapaki et al. · 2015 · Journal of Alzheimer s Disease
10. Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits
    Caroline Bouter, Jonathan S. Vogelgsang, Jens Wiltfang · 2019 · Clinica Chimica Acta
11. Sex differences in the association between amyloid and longitudinal brain volume change in cognitively normal older adults
    Nicole M. Armstrong, Chiung-Wei Huang, Owen A. Williams, Murat Bilgel, Yang An, Jimit J. Doshi, Güray Erus, Christos A. Davatzikos, Dean Foster Wong, Luigi Ferrucci et al. · 2019 · NeuroImage Clinical
12. PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
    Juhan Reimand, Arno de Wilde, Charlotte Elisabeth Teunissen, Marissa Deborah Zwan, Albert D. Windhorst, Ronald Boellaard, Frederik Barkhof, Wiesje M. van der Flier, Philip Scheltens, Bart N.M. van Berckel et al. · 2019 · Alzheimer s Research & Therapy
13. Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer’s Disease Prior to Overt Global Amyloid Positivity
    Doaa G. Ali, Ahmed Ali Bahrani, Justin M. Barber, Riham H. El Khouli, Brian T. Gold, Jordan P. Harp, Yang Jiang, Donna M. Wilcock, Gregory A. Jicha · 2022 · Journal of Alzheimer s Disease
14. Amyloid pathology in the progression to mild cognitive impairment
    Philip S. Insel, Oskar Hansson, R. Scott Mackin, Michael Walter Weiner, Niklas Mattsson · 2017 · Neurobiology of Aging
15. Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
    Aaron R. Ritter, Jeffrey L. Cummings · 2015 · Frontiers in Neurology
16. Cerebrospinal Fluid Amyloid Beta, Tau Levels, Apolipoprotein, and 1H-MRS Brain Metabolites in Alzheimer's Disease: A Systematic Review
    Albert Dayor Piersson, Mazlyfarina Mohamad, Fadilah Rajab, Subapriya Suppiah · 2020 · Academic Radiology
17. Neuronal clusterin expression is associated with cognitive protection in amyotrophic lateral sclerosis
    Jenna M. Gregory, Elizabeth Elliott, Karina McDade, Thomas H. Bak, Suvankar Pal, Siddharthan Chandran, Sharon Abrahams, Colin Smith · 2019 · Neuropathology and Applied Neurobiology
18. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
    Ina S. Almdahl, Camilla Lauridsen, Per Selnes, Lisa Flem Kalheim, Christopher S. Coello, Beata Gajdzik, Ina Møller, Marianne Wettergreen, Ramunė Grambaitė, Atle Bjørnerud et al. · 2017 · Frontiers in Aging Neuroscience
19. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting
    Na‐Yeon Jung, Eun Soo Kim, Hyang-Sook Kim, Sumin Jeon, Myung Jun Lee, Kyoungjune Pak, Jae‐Hyeok Lee, Young Min Lee, Kangyoon Lee, Jin‐Hong Shin et al. · 2020 · Journal of Alzheimer s Disease
20. The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
    Daniela Bertens, Betty Marije Tijms, Lisa Vermunt, Niels D. Prins, Philip Scheltens, Pieter Jelle Visser, Alzheimer’s Disease Neuroimaging Initiative · 2017 · Alzheimer s & Dementia Translational Research & Clinical Interventions
21. A blood-based signature of cerebrospinal fluid Aβ1–42 status
    Benjamin Goudey, Bowen John Fung, Christine Schieber, Noel Garry Faux, Michael Walter Weiner, Paul S. S. Aisen, Ronald Carl Petersen, Clifford R. Jack, William J. Jagust, John Q. Trojanowki et al. · 2019 · Scientific Reports
22. Biomarker‐based stability in limbic‐predominant amnestic mild cognitive impairment
    Giacomo Tondo, Giulia Carli, Roberto Santangelo, Maria Vittoria Mattoli, Luca Presotto, Massimo Filippi, Giuseppe Magnani, Sandro Iannaccone, Chiara Cerami, Daniela Perani et al. · 2020 · European Journal of Neurology
23. Cerebrospinal fluid dynamics and discordant amyloid biomarkers
    Jonathan Graff‐Radford, David Thomas Jones, Heather J. Wiste, Petrice M. Cogswell, Stephen D. Weigand, Val J. Lowe, Benjamin D. Elder, Prashanthi Vemuri, Argonde C. van Harten, Michelle M. Mielke et al. · 2021 · Neurobiology of Aging
24. Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease
    Emelie Andersson, Nina Schultz, Takashi Saito, Takaomi C. Saido, Kaj Blennow, Gunnar K. Gouras, Henrik Zetterberg, Oskar Hansson · 2023 · Alzheimer s Research & Therapy
25. Memory-Related Frontal Brainwaves Predict Transition to Mild Cognitive Impairment in Healthy Older Individuals Five Years Before Diagnosis
    Yang Jiang, Juan Li, Frederick A. Schmitt, Gregory A. Jicha, Nancy B. Munro, Xiaopeng Zhao, Charles D. Smith, Richard J. Kryscio, Erin L. Abner · 2020 · Journal of Alzheimer s Disease
26. Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts
    Raffaele Cacciaglia, Gemma Salvadó, José Luís Molinuevo, Mahnaz Shekari, Carles Falcón, Grégory Operto, Marc Suárez‐Calvet, Marta Milà‐Alomà, Arianna Sala, Elena Rodriguez‐Vieitez et al. · 2022 · Molecular Psychiatry
27. Reproducibility of Alzheimer’s Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions
    Jonathan S. Vogelgsang, Dirk Wedekind, Caroline Bouter, Hans-W. Klafki, Jens Wiltfang · 2018 · Journal of Alzheimer s Disease
28. CSF biomarkers in Olmsted County
    A. V. Van Harten, H. Wiste, S. Weigand, M. Mielke, W. Kremers, U. Eichenlaub, R. Batrla-Utermann, Roy B. Dyer, A. Algeciras-Schimnich, D. Knopman et al. · 2020 · Neurology
29. Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer’s dementia: a comparison of methods
    Alzheimer’s Disease Neuroimaging Initiative, A Sörensen, Ganna Blazhenets, Florian Schiller, Philipp Tobias Meyer, Lars Frings · 2020 · Alzheimer s Research & Therapy
30. Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
    Dmitry V. Zaretsky, Maria V. Zaretskaia, Yaroslav I. Molkov, Alzheimer’s Disease Neuroimaging Initiative · 2022 · PLoS ONE
31. Translating blood biomarkers into clinical practice for Alzheimer's disease: Challenges and perspectives
    Jun Wang, Ming Chen, Colin Louis Masters, Yan‐Jiang Wang · 2023 · Alzheimer s & Dementia
32. Circulating insulin-like growth factor 1 and insulin-like growth factor binding protein-3 level in Alzheimer’s disease: a meta-analysis
    Xiaohui Hu, Yan Yang, Daokai Gong · 2016 · Neurological Sciences
33. What does it mean to be ‘amyloid-positive’?
    Anne M. Fagan · 2015 · Brain
34. Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes
    Philip S.J. Weston, Ross W. Paterson, Marc Modat A, Ninon Burgos, M. Jorge Cardoso, Nadia K. Magdalinou, Manja Lehmann, John C. Dickson, Anna Barnes, Jamshed B Bomanji et al. · 2015 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
35. Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile
    Marta Milà‐Alomà, Mahnaz Shekari, Gemma Salvadó, Juan Domingo Gispert, Eider M. Arenaza‐Urquijo, Grégory Operto, Carles Falcón, Natàlia Vilor‐Tejedor, Oriol Grau‐Rivera, Aleix Sala‐Vila et al. · 2021 · Alzheimer s Research & Therapy
36. Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers
    Val J. Lowe, Carly T. Mester, Emily S. Lundt, Jeyeon Lee, Sujala Ghatamaneni, Alicia Algeciras‐Schimnich, Michelle Renee Campbell, Jonathan Graff‐Radford, Aivi T. Nguyen, Hoon-Ki Paul Min et al. · 2024 · Alzheimer s & Dementia
37. Multiplex connectome changes across the alzheimer’s disease spectrum using gray matter and amyloid data
    Anna Canal-García, Emiliano Gómez-Ruiz, Mite Mijalkov, Yu-Wei Chang, Giovanni Volpe, Joana B. Pereira, Alzheimer’s Disease Neuroimaging Initiative · 2021 · Cerebral Cortex
38. It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimer’s and Lewy Body Disease Spectra
    Noritaka Wakasugi, Takashi Hanakawa · 2021 · Frontiers in Systems Neuroscience
39. Critical Comparison of Different Biomarkers for Alzheimer’s Disease in a Clinical Setting
    David Weise, Solveig Tiepolt, Carolin Awissus, Karl‐Titus Hoffmann, Donald Lobsien, Thorsten Kaiser, Henryk Barthel, Osama Sabri, Hermann‐Josef Gertz · 2015 · Journal of Alzheimer s Disease
40. AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention
    Pierre‐François Meyer, Melissa McSweeney, Julie Gonneaud, Sylvia Villeneuve · 2019 · Progress in molecular biology and translational science
41. Longitudinal Metabolite Profiling of Cerebrospinal Fluid in Normal Pressure Hydrocephalus Links Brain Metabolism with Exercise-Induced VEGF Production and Clinical Outcome
    He Huang, Jun Yang, Mark Gregory Luciano, Leah P. Shriver · 2016 · Neurochemical Research
42. Lower Locus Coeruleus Integrity Signals Elevated Entorhinal Tau and Clinical Progression in Asymptomatic Older Individuals
    Nina Engels, Joost M. Riphagen, Maxime Van Egroo, Elouise A. Koops, Lindsay F. Smegal, John Alex Becker, Prokopis C. Prokopiou, Elisenda Bueichekú, Kenneth K. Kwong, Dorene M. Rentz et al. · 2024 · Annals of Neurology
43. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson’s Disease—A Preliminary Report
    Rui Gao, Guangjian Zhang, Xueqi Chen, Aimin Yang, Gwenn S. Smith, Dean Foster Wong, Yun Zhou · 2016 · PLoS ONE
44. Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
    Giulia Giacomucci, Salvatore Mazzeo, Silvia Bagnoli, Matteo Casini, Sonia Padiglioni, Cristina Polito, Valentina Berti, Juri Balestrini, Camilla Ferrari, Gemma Lombardi et al. · 2021 · Journal of Personalized Medicine
45. The pathway to secondary prevention of Alzheimer's disease
    McDade, Eric, Bednar, Martin M., Brashear, H. Robert, Miller, David S., Maruff, Paul, Randolph, Christopher, Ismail, Zahinoor, Carrillo, Maria C., Weber, Christopher J., Bain, Lisa J. et al. · 2020 · Alzheimer's & Dementia: Translational Research & Clinical Interventions
46. Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease
    Rong-Rong Lin, Yan‐Yan Xue, Xiaoyan Li, Yi-He Chen, Qing‐Qing Tao, Zhi‐Ying Wu · 2021 · Frontiers in Aging Neuroscience
47. The cross-sectional association between amyloid burden and white matter hyperintensities in older adults without cognitive impairment: A systematic review and meta-analysis
    Emma L. Twait, Britt Min, Magdalena Beran, Jet M. J. Vonk, Mirjam I. Geerlings · 2023 · Ageing Research Reviews
48. Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity
    Sophie E Mastenbroek, Arianna Sala, David Vállez García, Mahnaz Shekari, Gemma Salvadó, Luigi Lorenzini, Leonard Pieperhoff, Alle Meije Wink, Isadora Lopes Alves, Robin Wolz et al. · 2024 · Neurology
49. Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?
    Joshua D. Grill, Michelle M. Nuño, Daniel L. Gillen · 2019 · Alzheimer Disease & Associated Disorders
50. Associations of hippocampal volumes, brain hypometabolism, and plasma NfL with amyloid, tau, and cognitive decline
    Fengfeng Pan, Qi Huang, Chu‐Chung Huang, Yao Wei Lu, Liang Cui, Lin Huang, Yihui Guan, Fang Xie, Qihao Guo · 2025 · Alzheimer s & Dementia
51. Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology
    Natalya Benina, Luna Buitrago, Francesca I De Simone, Rachel R. Radwan, M. Craig Miller, Katie Martin, Diana L. Dickson, Sara G. Ho, Abhay Moghekar, Marilyn Albert et al. · 2026 · Brain
52. Patterns of Early Neocortical Amyloid-β Accumulation: A PET Population-Based Study
    Emily E. Lecy, Hoon-Ki Paul Min, Christopher J. Apgar, Daniela D. Maltais, Emily S. Lundt, Sabrina M. Albertson, Matthew L. Senjem, Christopher G. Schwarz, Hugo Botha, Jonathan Graff‐Radford et al. · 2024 · Journal of Nuclear Medicine
53. Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
    Xue‐Ning Shen, Kevin Kuo, Yuxiang Yang, Hong‐Qi Li, Shi‐Dong Chen, Mei Cui, Lan Tan, Qiang Dong, Jin‐Tai Yu, Alzheimer’s Disease Neuroimaging Initiative · 2021 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
54. Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
    Piotr Lewczuk, Jens Wiltfang, Johannes Kornhuber, Anneleen Verhasselt · 2021 · Diagnostics
55. β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns
    Chenyang Jiang, Qingyong Wang, Siwei Xie, Zhicheng Chen, Liping Fu, Qiyu Peng, Ying Liang, Hongbo Guo, Tengfei Guo, Alzheimer’s Disease Neuroimaging Initiative · 2022 · Brain Communications
56. Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults
    Jolien M. Schaeverbeke, Benjamin Gille, Katarzyna Adamczuk, Hugo Vanderstichele, Emeric Chassaing, Rose Bruffaerts, Veerle Neyens, Erik Stoops, Jos Tournoy, Rik R. Vandenberghe et al. · 2019 · Journal of Neurochemistry
57. Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data
    Young Chul Youn, Hye Ryoun Kim, Hae-Won Shin, Hae-Bong Jeong, Sang‐Won Han, Jung‐Min Pyun, Nayoung Ryoo, Young Ho Park, SangYun Kim · 2022 · BMC Medical Informatics and Decision Making
58. Will PET Amyloid Imaging Lead to Overdiagnosis of Alzheimer Dementia?
    Jacob G. Dubroff, Ilya M. Nasrallah · 2015 · Academic Radiology
59. Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum
    Lyduine Eisa Collij, Gemma Salvadó, Kanta Horie, Nicolas R. Barthélemy, Tobey J. Betthauser, Olof T. Strandberg, Ruben A Smith, Sebastian Palmqvist, Suzanne E. Schindler, Rik Ossenkoppele et al. · 2026 · Nature Communications
60. Positron Emission Tomography/Computed Tomography Imaging in Therapeutic Clinical Trials in Alzheimer’s Disease: An Overview of the Current State of the Art of Research
    Elizabeth Katherine Anna Triumbari, Agostino Chiaravalloti, Orazio Schillaci, Nicola Biagio Mercuri, Claudio Liguori · 2024 · Journal of Alzheimer s Disease
61. Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
    Takeshi Iwatsubo, Reisa Anne Sperling, Alicia Algeciras‐Schimnich, Hidenori Arai, Anna M. Barron, Tammie L.S. Benzinger, Marı́a C. Carrillo, Christopher Chen, Seong Hye Choi, Igor Camargo Fontana et al. · 2025 · Alzheimer s & Dementia
62. Preclinical Alzheimer’s Disease: Implications for Refinement of the Concept
    Stephanie J. B. Vos, Pieter Jelle Visser · 2018 · Journal of Alzheimer s Disease
63. Amyloid beta–positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity
    Brian Avants, R. Matthew Hutchison, Alvydas Mikulskis, Cristian Salinas-Valenzuela, Richard Hargreaves, John D. Beaver, Ping Chiao · 2018 · Neurobiology of Aging
64. Aβ status assessment in a hypothetical scenario prior to treatment with disease‐modifying therapies: Evidence from 10‐year real‐world experience at university memory clinics
    Matthias Brendel, Tandis Parvizi, Johannes S. Gnörich, Christof Elias Topfstedt, Katharina Büerger, Daniel Janowitz, Boris‐Stephan Rauchmann, Robert Perneczky, Carolin Kurz, Dirk Mehrens et al. · 2024 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
65. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer’s Disease: Shortcomings in Prodromal Diagnosis
    Levente Szalárdy, Dénes Zádori, Péter Klivènyi, László Vécsei · 2016 · Journal of Alzheimer s Disease
66. Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial
    Anna Rosenberg, Alina Solomon, Hilkka S. Soininen, Pieter Jelle Visser, Kaj Blennow, Tobias Hartmann, Miia Kivipelto, Hilkka S. Soininen, Ilona Tuulia Hallikainen, Merja Hallikainen et al. · 2021 · Alzheimer s Research & Therapy
67. A Practical Approach for the Detection of Protein Tau with a Portable Potentiostat
    Münteha Nur Sonuç Karaboğa, Mustafa Kemal Sezgintürk · 2022 · Electroanalysis
68. Models of precision medicine for neurodegeneration
    Alberto Javier Espay · 2023 · Handbook of clinical neurology
69. Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer’s Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins
    Chloé Manca, Lucie Hopes, Anna Kearney‐Schwartz, Véronique Roch, Gilles Karcher, Cédric Baumann, Pierre‐Yves Marie, Catherine Malaplate, Thérèse Jonveaux, Antoine Verger · 2019 · Journal of Alzheimer s Disease
70. Biomarker pathway heterogeneity of amyloid‐positive individuals
    Lloyd Prosser, Carole H. Sudre, Neil P. Oxtoby, Alexandra L. Young, Ian B. Malone, Emily Ndakola Manning, Hugh Pemberton, Phoebe Walsh, Frederik Barkhof, Geert Jan Biessels et al. · 2024 · Alzheimer s & Dementia
71. Amyloid biomarkers: pushing the limits of early detection
    Gil Dan Rabinovici · 2016 · Brain
72. Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes
    Jung‐Min Pyun, Young Ho Park, Min Ju Kang, SangYun Kim · 2024 · Alzheimer s Research & Therapy
73. Cortical Diffusivity, a Biomarker for Early Neuronal Damage, Is Associated with Amyloid-β Deposition: A Pilot Study
    Justine Debatisse, Fangda Leng, Azhaar Ashraf, Paul Edison · 2025 · Cells
74. The Diagnostic and Therapeutic Potential of Oligonucleotide Aptamers in Alzheimer’s Disease
    Georgios Katsipis, Elena E. Tzekaki, Sophia Iasonidou, Αnastasia A. Pantazaki · 2025 · Cells
75. Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?
    Piotr Lewczuk, Johannes Kornhuber · 2016 · Brain
76. Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study
    Marcos Vasconcelos Pais, Júlia Cunha Loureiro, Vagner Santiago do Vale, Márcia Radanovic, Leda Leme Talib, Florindo Stella, Orestes Vicente Forlenza · 2021 · Journal of Alzheimer s Disease
77. Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer’s Disease Spectrum: Who Really Deserves an A+?
    Luca Sacchi, Tiziana Carandini, Giorgio Fumagalli, Anna Margherita Pietroboni, Valeria Elisa Contarino, Silvia Siggillino, Marina Arcaro, Chiara Fenoglio, Felicia Zito, Giorgio Marotta et al. · 2021 · Journal of Alzheimer s Disease
78. Genome-wide association study identifies CBFA2T3 affecting the rate of CSF Aβ42 decline in non-demented elders
    Kaixin Dou, Alzheimer’s Disease Neuroimaging Initiative, Can Martin Zhang, Chen‐Chen Tan, Wei Xu, Jieqiong Li, Xi‐Peng Cao, Lan Tan, Jin‐Tai Yu · 2019 · Aging
79. Third Ventricle Width Assessed by Transcranial Sonography as Predictor of Long-Term Cognitive Impairment
    Ane Miren Crespo-Cuevas, Elena López-Cancio M., Cynthia M. Cáceres, Anna González, Lourdes Ispierto, María Hernández‐Pérez, María Mataró, Anna Maria Planas, Tamara Canento, Lorena Martín-Aguilar et al. · 2019 · Journal of Alzheimer s Disease
80. Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative
    Renée C. Groechel, Yorghos Tripodis, Michael Louis Alosco, Jesse Mez, Wei Qiao Qiu, Gustavo Mercier, Lee E. Goldstein, Andrew E. Budson, Neil W. Kowall, Ronald Killiany · 2023 · Neurobiology of Aging
81. Diagnostic de la maladie d’Alzheimer : apport de l’imagerie au florbétapir et autres radiopharmaceutiques de la plaque amyloïde
    Franck Semah, Walter G. Deberdt, Mathieu Pierre Ceccaldi · 2016 · Médecine Nucléaire
82. The pitfalls of biomarker‐based classification schemes
    Ignacio Illán‐Gala, Eduard Vilaplana, Jordi Pegueroles, Víctor Montal, Daniel Andres Alcolea, Rafael Blesa, Alberto Lleó, Juan Fortea · 2017 · Alzheimer s & Dementia
83. Challenges in Alzheimer’s Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences
    Gemma Lombardi, Alberto Pupi, Valentina Bessi, Cristina Polito, Sonia Padiglioni, Camilla Ferrari, Giulia Lucidi, Valentina Berti, Maria Teresa De Cristofaro, Irene Piaceri et al. · 2020 · Journal of Alzheimer s Disease
84. Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?
    Sebastian Palmqvist, Niklas Mattsson, Oskar Hansson · 2016 · Brain
85. Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer’s Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma
    Lingyu Zhang, Danhua Wang, Yibei Dai, Xuchu Wang, Ying Cao, Weiwei Liu, Zhihua Tao · 2022 · Frontiers in Aging Neuroscience
86. Towards the Integrative Theory of Alzheimer’s Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis
    Yaroslav I. Molkov, Maria V. Zaretskaia, Dmitry V. Zaretsky, the Alzheimer’s Disease Neuroimaging Initiative · 2023 · Current Alzheimer Research
87. Association of cigarette smoking with cerebrospinal fluid biomarkers of insulin sensitivity and neurodegeneration
    Fan Wang, Hui Li, Tiantian Kong, Ligang Shan, Jiajia Guo, Yan Wu, Xingguang Luο, Senthil Kumaran Satyanarayanan, Kuan‐Pin Su, Yanlong Liu · 2024 · Brain and Behavior
88. Early β-amyloid accumulation and hypoconnectivity in the default mode network are related to its disengagement from global brain activity
    Feng Han, Xufu Liu, Richard B. Mailman, Xuemei Huang, Xiao Liu, the Alzheimer’s Disease Neuroimaging Initiative · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
89. Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements
    Matilde Nerattini, Federica Rubino, Annachiara Arnone, Cristina Polito, Salvatore Mazzeo, Gemma Lombardi, Giulia Puccini, Benedetta Nacmias, Maria Teresa De Cristofaro, Sandro Sorbi et al. · 2021 · Neurological Sciences
90. The fractional amplitude of low-frequency fluctuations signals related to amyloid uptake in high-risk populations—A pilot fMRI study
    Yi‐Wen Bao, Yat Fung Shea, Patrick Ka‐Chun Chiu, Joseph S. K. Kwan, Felix Hon-Wai Chan, Wing-Sun Chow, Koon‐Ho Chan, Henry Ka‐Fung Mak · 2022 · Frontiers in Aging Neuroscience
91. Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO
    Raquel Puerta, Itziar de Rojas, Pablo García‐González, Clàudia Olivé, Óscar Sotolongo‐Grau, Ainhoa García‐Sánchez, Fernando García‐Gutiérrez, Laura Montrreal, Juan Pablo Tartari, Ángela Sanabria et al. · 2025 · Functional & Integrative Genomics
92. Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance
    David S. Knopman, Stephen D. Weigand, Heather J. Wiste, Jonathan Graff‐Radford, Neill R. Graff‐Radford, Ronald Carl Petersen, Bradley F. Boeve, Clifford R. Jack, Val J. Lowe, Mary M. Machulda et al. · 2025 · Alzheimer s & Dementia
93. Two Routes to Alzheimer’s Disease Based on Differential Structural Changes in Key Brain Regions
    Yasmin Hollenbenders, Alzheimer’s Disease Neuroimaging Initiative, Monika Pobiruchin, Alexandra Reichenbach · 2023 · Journal of Alzheimer s Disease
94. Clinical value of Alzheimer's disease biomarker testing
    Khushbu J. Patel, David Yang, John R. Best, Colleen Chambers, Philip E. Lee, Alexandre Henri‐Bhargava, Clark R. Funnell, Dean J. Foti, Jacqueline A. Pettersen, Howard Feldman et al. · 2024 · Alzheimer s & Dementia Translational Research & Clinical Interventions
95. PSEN2 Thr421Met Mutation in a Patient with Early Onset Alzheimer’s Disease
    YoungSoon Yang, Eva Bagyinszky, Seong Soo A. An, SangYun Kim · 2022 · International Journal of Molecular Sciences
96. The Default Mode Network and Executive Function
    Christopher Brown · 2017 · UKnowledge (University of Kentucky)
97. Comparison of Amyloid in Cerebrospinal Fluid, Brain Imaging, and Autopsy in a Case of Progressive Supranuclear Palsy
    Kyung Hye Kim, Jae Deuk Seo, Eun Soo Kim, Hyang-Sook Kim, Sumin Jeon, Kyoungjune Pak, Myung Jun Lee, Jae‐Hyeok Lee, Young Min Lee, Kangyoon Lee et al. · 2020 · Alzheimer Disease & Associated Disorders
98. Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei.
    Kai-Hsi Hsu, Cheng-Yang Chou, Yu-Chung Chang · 2007 · PubMed
99. Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia
    Fredrik Öhman, Lars Lau Rakêt, Michael Schöll, Alzheimer’s Disease Neuroimaging Initiative · 2026 · Advanced Science
100. Brain PET in the era of anti-amyloid-β antibody therapy for Alzheimer disease
     Kazunari Ishii · 2026 · Japanese Journal of Radiology